August 30, 2022: “Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.
“We are excited to share the data being presented across our portfolio of cancer therapies, which reinforce our commitment to pursuing every possible approach to address the urgent and significant unmet medical needs of people living with cancer,” said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development, Novartis.
“Our presentations at ESMO will highlight our continued dedication to advancing innovative treatment options for these critical diseases.”
Key highlights of data accepted by ESMO:
| Medicine | Abstract Title | Abstract Number/ Presentation Details |
| Kisqali® (ribociclib)* | Pooled exploratory analysis of survival in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials | Abstract #205P Poster Session Saturday, September 10 |
| Kisqali® (ribociclib)* | HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)† | Abstract # 272TiP Poster Session Saturday, September 10 |
| Piqray® (alpelisib) | BYLieve trial (alpelisib [ALP] + endocrine therapy [ET]) versus real-world (RW) standard of care (SOC) in patients (pts) with PIK3CA-mutated (mut), hormone receptor-2 positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced 3 breast cancer (ABC) who progressed on cyclin-dependent kinase 4/6 inhibitor (CDKi) 4 therapy (tx) | Abstract #222P Poster Session Saturday, September 10 |
| Tislelizumab | Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma | Abstract #LBA36 Proffered Paper Session Saturday, September 10 09:15 – 09:25 AM CEST |
| Tislelizumab | Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study | Abstract #1031P Poster Session Monday, September 12 |
| Pluvicto™ (lutetium 177Lu vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) | Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial | Abstract #1372P Poster Session Sunday, September 11 |
| Pluvicto™ (lutetium 177Lu vipivotide tetraxetan) | Radiographic progression-free survival correlation with patient-relevant outcomes: a post hoc analysis of time-to-event endpoints of the VISION trial | Abstract #1374P Poster Session Sunday, September 11, |
| Prostate Cancer | Quality of life across three countries using a large-scale, fully digital survey of patients with prostate cancer | Abstract #1401P Poster Session Sunday, September 11 |
| Canakinumab (ACZ885) | CANOPY-A: phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC) | Abstract #LBA49 Proffered Paper Session Sunday, September 11 09:20 – 09:30 AM CEST |
| Vijoice® (alpelisib) | Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): an EPIK-P1 analysis | Abstract #468P Poster Session Monday, September 12 |
Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit
https://www.novartisoncology.com/news/product-portfolio.
